Related Experiment Video
Updated: Sep 28, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer
Elizabeth Turpin1, Ivan Bièche, Philippe Bertheau
1Service de Biochimie B and CNRS UPR9051, Hôpital Saint Louis, 1, Avenue Claude Vellefaux, F-75475 Paris Cedex 10, France.
Abstract:
Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. We studied the biological characteristics of these tumours by comparing the overexpression of oncogenes ERBB2, MYC, CCND1 and RHOC and TP53 gene mutation rates in IBC with those found in locally advanced and not otherwise specified breast cancers. The prevalence of the TP53 mutation was much higher in IBC than in the two other types of cancer (57% vs 30). Unexpectedly, however, in IBC tumours, histological grade was independent of TP53 status. In addition, ERBB2 overexpression was twice as frequent in inflammatory as in non-inflammatory tumours, whereas the frequencies of MYC, CCND1 and RHOC overexpression did not vary significantly among the three types of breast cancer. These findings suggest that IBC tumours constitute a distinct subset with a specific pathogenesis. Given the importance of TP53 and ERBB2 in the response to treatments, our observations have important therapeutic implications for the clinical management of IBC patients.
Related Concept Videos
Mitogens and the Cell Cycle
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inflammatory Bowel Disease III: Crohn's Disease
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Tumor Microenvironment